Sacubitril/Valsartan for the Prevention and Treatment of Postinfarction Heart Failure: Ready to Use?

Saved in:
Bibliographic Details
Published inJournal of cardiovascular pharmacology Vol. 78; no. 3; p. 331
Main Authors Del Buono, Marco G, Damonte, Juan I, Trankle, Cory R, Bhardwaj, Hem, Markley, Roshanak, Turlington, Jeremy, Van Tassell, Benjamin W, Salloum, Fadi N, Abbate, Antonio
Format Journal Article
LanguageEnglish
Published United States 01.09.2021
Subjects
Aminobutyrates - adverse effects
Aminobutyrates - therapeutic use
Angiotensin II Type 1 Receptor Blockers - adverse effects
Angiotensin II Type 1 Receptor Blockers - therapeutic use
Animals
Biphenyl Compounds - adverse effects
Biphenyl Compounds - therapeutic use
Clinical Decision-Making
Disease Models, Animal
Drug Combinations
Evidence-Based Medicine
Heart Disease Risk Factors
Heart Failure - diagnosis
Heart Failure - mortality
Heart Failure - prevention & control
Humans
Myocardial Infarction - diagnosis
Myocardial Infarction - drug therapy
Myocardial Infarction - mortality
Neprilysin - antagonists & inhibitors
Protease Inhibitors - adverse effects
Protease Inhibitors - therapeutic use
Protective Factors
Risk Assessment
Treatment Outcome
Valsartan - adverse effects
Valsartan - therapeutic use
Online AccessGet more information

Cover

More Information
ISSN:1533-4023
DOI:10.1097/FJC.0000000000001103